Uveitis – Pipeline Review, 2024

An inflammation of the uvea is known as uveitis. Eye injury or inflammatory diseases may lead to uveitis. There are four types of uveitis such as anterior uveitis, posterior uveitis, intermediate uveitis, and diffuse uveitis. More than 280,000 people affected by uveitis in the U.S. each year. Anterior uveitis is the most common form of uveitis with an incidence rate of 8 to 15 cases per 100,000 people annually. The symptoms of uveitis include light sensitivity, eye pain, decreased visual acuity, red eyes, etc. Uveitis may cause due to fungal, viral, and bacterial infections.

The primary medication for anterior uveitis is eye drops which dilate the pupil and prevent muscle spasms in the iris and ciliary body. The use of medicines to eliminate inflammation, prevent further tissue damage, alleviate pain, and restore any loss of vision is the primary goal. Immunosuppressants and other medications such as azathioprine, methotrexate, cyclosporine, and mycophenolate are being used for the treatment of uveitis. Biologic response modifiers or biologics, such as infliximab, adalimumab, rituximab daclizumab, and abatacept are also used to treat uveitis.

Research laboratories and academic research institutes have focused on studying and developing new treatment options for the uveitis. For instance; ADX-102, which is being studied by Aldeyra Therapeutics, is currently in phase-3 clinical trials in subjects with non-infectious anterior-uveitis.

To know how our report can help streamline your business, Speak to Analyst

At present more than 60% of the pipeline candidates for liposarcoma are in the phase-2 and phase-3 stage. Majority of the studies have been sponsored by universities and research institutes. 

Report Description

The report on ‘Uveitis – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Uveitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Uveitis.

The report on ‘Uveitis – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Uveitis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Uveitis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary